How Woozle Helped a CDD Consultant to Source 50 Preclinical Oncology Decision-Makers Across 3 Continents in 2 Weeks

Running primary research on the preclinical oncology outsourcing market is not a straightforward procurement exercise. The companies that operate in this space — specialist contract research organisations offering patient-derived xenograft models, organoid platforms, and multi-omics services to pharma and biotech R&D teams — are used by a small, senior, and time-scarce population. The decision-makers who select and evaluate these vendors are not clinical or commercial professionals. They are translational scientists, oncology R&D leads, and biomarker development heads operating at VP and Director level, deep inside pharma and biotech organisations where their time is finite and their patience for irrelevant survey invitations is nonexistent.

A commercial due diligence consultant running a market study on the preclinical oncology services sector came to Woozle with a brief that most sample vendors had either declined or underpriced to the point of being implausible. The study required 50 verified completes across North America, Europe, and Asia-Pacific. The qualifying criteria were narrow: pharma and biotech respondents only, active oncology programmes, current users of external preclinical model services, and genuine vendor-selection authority. The survey ran to 20 minutes. The client needed the programme launched and fielded within a defined due diligence window.

Most panel vendors either quoted a CPI that assumed the audience was easier to find than it is, or they passed on the brief entirely. Neither outcome was useful.

How the Old Model Actually Worked

The agency had run similar specialist B2B studies through panel aggregators before. The process was familiar: submit the qualifying criteria, receive a CPI, launch the survey link, wait for completes to accumulate. For broad healthcare professional audiences — physicians, nurses, general pharma — this model works. Incidence rates are high, panels are large, and the CPI stays within range.

For VP-level preclinical oncology R&D leaders, it doesn't.

The panel aggregator model prices surveys against its database. When a qualifying audience is genuinely rare — Director to VP, active oncology programme, current external service user, vendor-selection authority — the database doesn't contain what the brief requires. The vendor either soft-screens to fill the quota faster, or they field slowly while the client's project timeline slips. In either case, the consultant ends up managing the fallout: low data quality, recontact requests, cell failures in the markets that matter most.

On a previous CDD engagement in a comparable specialist segment, the consultant had seen a panel vendor deliver 40 completes that appeared to qualify on paper and fell apart during data cleaning. Twelve respondents couldn't accurately describe the services they claimed to be using. Seven had no vendor-selection involvement beyond being copied on procurement emails. The dataset required a partial refield that cost more time than the original programme.

The APAC cells compounded the problem. Ten to fifteen completes across Japan, China, Korea, Australia, India, and South East Asia at VP-level preclinical seniority cannot be sourced from a global panel. Each market requires direct outreach. China and South East Asia at this profile depth require bespoke recruitment in-country. For a panel aggregator pricing at standard CPI, the economics don't support that effort.

Why They Switched

The consultant had worked with Woozle on an earlier expert call programme and understood the model. Woozle doesn't pull from a pre-built panel. Every respondent is recruited fresh for the project using direct outreach via LinkedIn, professional networks, and Woozle's pharma and biotech expert community — verified against the qualifying criteria before they receive the survey link.

The proposition for this brief was straightforward: Woozle would field 50 completes at $200 CPI, screened to spec, with full verification of respondent profiles before data delivery. The qualifying logic would be enforced at recruitment, not inferred from self-reported answers. Every complete would be a real VP or Director-level leader inside a pharma or biotech organisation, running an active oncology programme, with genuine familiarity with the specialist CRO market.

The CPI was higher than commodity panel rates. It reflected what the audience actually costs to find.

The economics held up against the alternative. A partial refield on 50 completes sourced at lower CPI costs more — in time, in client relationships, and in recontact fees — than fielding correctly at $200 per complete from the start.

How It Played Out

Recruitment began within 24 hours of the brief being confirmed. Woozle's sourcing team mapped the qualifying population across the three regions: translational science, preclinical pharmacology and biology, oncology R&D, biomarker leadership, and computational biology functions at Director to VP level inside pharma and biotech organisations. Academic institutions, CROs, consulting firms, device companies, and diagnostics businesses were excluded at the sourcing stage, not the screening stage.

North America and Europe filled first. By the end of week one, 32 verified completes were in — a mix of large pharma and emerging biotech respondents, balanced across solid tumour, haematological, and IO programme types, covering the full range of modality areas required: ADC, radiopharma, targeted therapy, IO, bispecifics, cell therapy, and protein degraders.

The APAC cells were sourced in parallel through direct outreach to Woozle's pharma and biotech expert network across Japan, Korea, and Australia, with targeted recruitment in China and South East Asia through local outreach partners. These cells took longer — the seniority and screening depth made each complete a genuine sourcing effort — but by the end of week two, the full programme of 50 verified completes was closed.

The consultant had a complete, clean dataset within the due diligence window. Every respondent had been individually verified before the survey link was issued. The project timeline held.

The Results

Fifty verified completes delivered in six business days. Zero soft completes. Every respondent individually recruited and checked against the qualifying criteria before receiving the survey link.

The North American and European cells closed ahead of schedule, with company-size balance achieved across large pharma, mid-size pharma, small biotech, and emerging biotech without any recontact or replacement required. The modality spread — across seven oncology treatment types — was achieved within the target completes rather than requiring oversampling and pruning.

The APAC cells, historically the hardest to field in specialist B2B healthcare, closed at ten completes across five markets. Japan, Korea, Australia, China, and South East Asia were all represented. Every APAC respondent was VP or Director level. Every one had an active oncology programme and current external model service usage.

Data cleaning identified no respondents for removal. The dataset went to analysis intact.

"We've run a lot of specialist B2B panels. This is the first time we've received 50 completes and not had to remove a single one in cleaning. That's not a small thing — it changes the whole project economics when you don't have to refield."

Senior Project Manager

The total programme cost was approximately $10,000 against 50 verified completes — $200 per complete. Against the counterfactual of a commodity panel at lower CPI followed by a partial refield, the delivered cost per usable complete was lower, not higher.

The Structural Difference

The difference between this programme and a standard panel delivery is not incremental. It is a function of how respondents are sourced.

Panel vendors price against their database. When a brief falls within their coverage — broad professional categories, common specialisms, established geographies — the model works and the CPI reflects genuine supply. When a brief falls outside that coverage, the vendor has two options: decline, or quote the standard CPI and hope the screening catches enough qualifying respondents in the field. The second option produces soft completes, failed cells, and refields.

Woozle prices against the actual cost of recruitment for the audience specified. Every respondent is sourced directly — via LinkedIn, professional networks, and the Woozle pharma and biotech expert community — and verified against the qualifying criteria before the survey link is issued. There is no database pull. There is no assumption that the population is larger or easier to reach than it is. The CPI reflects the work.

For broad B2B healthcare audiences, the gap between panel and Woozle pricing is narrow. For VP-level preclinical oncology R&D leaders with active programmes and vendor-selection authority, it is not. The choice is not between an expensive option and an affordable one. It is between a programme that delivers the audience specified and one that approximates it.

"You can price a panel low or you can price it right. On a brief like this, low and right are not the same number."

Research Director

Looking Ahead

The consultant has since briefed Woozle on two additional specialist B2B healthcare programmes — one assessing the diagnostics procurement market, one covering medical affairs leadership in rare disease. Both shared the same structural challenge as the preclinical oncology study: a small, senior, hard-to-reach audience that standard panels struggle to field at spec.

The working model is consistent across both programmes. Woozle handles recruitment and verification. The consultant retains scripting, hosting, and analysis. The division of labour plays to both parties' strengths.

"The projects where we come to Woozle are the ones where we know the panel route is going to cause problems. It's become a reliable answer to a specific question: where do you go when the audience is too senior and too narrow for a standard panel to field cleanly?"

CDD Consultant

About Woozle Research

Woozle is the primary research platform that delivers answers, not access. Trusted by leading hedge funds, private equity firms, and strategy consultancies, Woozle replaces the friction, cost, and uncertainty of traditional expert networks with verified, decision-ready intelligence delivered in days. The platform combines AI-powered expert sourcing with human-led research execution, delivering structured expert calls, surveys, and analysis through a real-time portal. Every insight is verified, triangulated, and exclusive to the client.

To learn more or request a pilot: sales@woozleresearch.com